Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.
Saved in:
| Title: | Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma. |
|---|---|
| Authors: | Ono A; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Hayes CN; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Kawaoka T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Tsuge M; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Liver Center, Hiroshima University Hospital, Hiroshima, Japan., Oka S; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. |
| Source: | Journal of gastrointestinal oncology [J Gastrointest Oncol] 2026 Apr 30; Vol. 17 (2), pp. 114. Date of Electronic Publication: 2026 Apr 28. |
| Publication Type: | Editorial; Comment |
| Journal Info: | Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2078-6891 |
|---|---|
| DOI: | 10.21037/jgo-2025-aw-857 |
